Intelligence Platform
Patents
Browse 1,641 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 12228572
Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-inf
granted patentUS 12220455
Coronavirus vaccine compositions and methods
granted patentUS 12213989
Use of maribavir in treatment regimens
granted patentUS 12208093
Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
granted patentUS 12210017
Peptides representing epitopes from filoviruses
granted patentUS 12201658
Viral gene therapy as treatment for cholesterol storage disease or disorder
granted patentUS 12186363
Compositions and methods for dengue virus chimeric constructions in vaccines
granted patentUS 12188039
Recombinant adeno-associated viral vector for gene delivery
granted patentUS 12186342
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, I
granted patentUS 12187779
Anti-human papillomavirus 16 E6 T cell receptors
granted patentUS 12173029
Antiviral prodrugs, pharmaceutical formulations, and methods
granted patentUS 12172038
Anti-coronavirus antibodies and methods of use
granted patentUS 12173307
Methods for the purification of viral vectors
granted patentUS 12173289
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
granted patentUS 12168013
Antiviral prodrugs and nanoformulations thereof
granted patentUS 12168675
Virus-like particles and methods of use
granted patentUS 12162857
Antiviral compounds
granted patentUS 12156908
Virus like nanoparticle compositions and methods thereof
granted patentUS 12152067
Human antibodies to ebola virus glycoprotein
granted patentUS 12145941
Heterocyclic antiviral agents
granted patentUS 12138243
Antiviral use of FABP4 modulating compounds
granted patentUS 12129476
Methods for measuring the potency of AADC viral vectors
granted patentUS 12121503
Antiviral treatments
granted patentUS 12121567
Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase usin
granted